19 completed, 2 terminated, 2 withdrawn, 1 active not recruiting. 26 Phase 2, 6 Phase 1, 3 Phase 3.
Follow Carbidopa: new trials by email Literature Review of Carbidopa trials Research Report on Carbidopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 5 | 2024-10-29 | 2026-04-14 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 13 | 2024-03-15 | 2025-06-17 |
| Histaminergic Basis of Fatigue in Multiple Sclerosis L-Histidine, Placebo, Lodosyn - Multiple Sclerosis | Phase 2 | Withdrawn | University of Miami | 2022-01-01 | 2021-07-29 | |
| Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients continuous oral delivery of levodopa/carbidopa - Parkinson's Disease | Phase 2 | Completed | SynAgile Corporation | 17 | 2021-06-16 | 2022-08-10 |
| Dopaminergic Dysfunction in Late-Life Depression L-Dopa, Placebo - Late Life Depression, Cognitive Decline | Phase 2 | Completed | Vanderbilt University Medical Center | 79 | 2021-02-15 | 2026-08-06 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System carbidopa - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 14 | 2021-02-08 | 2024-04-04 |
| Effects of 5HTP on the Injured Human Spinal Cord 5-Hydroxytryptophan 100 MG, 5-Hydroxytryptophan, Carbidopa - Spinal Cord Injuries | Phase 2 / Phase 3 | Active not recruiting | University of Alberta | 6 | 2020-07-01 | 2026-09-16 |
| Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity carbidopa/levodopa and celecoxib, placebo1 and celecoxib, placebo1 and placebo2 - Chronic Back Pain | Phase 2 | Withdrawn | Second Affiliated Hospital of Wenzhou Medical University | 2019-10-01 | 2020-01-09 | |
| Effects of 5HTP and LDOPA on CNS Excitability After SCI 5HTP, L-DOPA, Placebo oral tablet - Spinal Cord Injuries | Phase 2 / Phase 3 | Suspended | Jessica M D'Amico | 30 | 2019-06-19 | 2022-10-17 |
| Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients Accordion Pill Carbidopa/Levodopa, Sinemet CR 25Mg-100Mg Extended-Release Tablet - Parkinson Disease | Phase 2 | Unknown | Intec Pharma Ltd. | 12 | 2018-07-01 | 2018-07-05 |
| Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal Placebo, L-dopa 35 mg, L-dopa 70mg - Parkinson's Disease | Phase 2 | Completed | Impel Pharmaceuticals | 32 | 2018-05-08 | 2020-08-12 |
| Carbidopa for the Treatment of Excessive Blood Pressure Variability Carbidopa Low-Dose, Placebo, Carbidopa High-Dose - Dysautonomia, Familial, Baroreflex Failure Syndrome | Phase 2 | Completed | NYU Langone Health | 22 | 2015-09-01 | 2022-02-09 |
| Antipsychotic Augmentation With L-Dopa levodopa/carbidopa (generic version of Sinemet) - Schizophrenia | Phase 2 | Completed | Centre for Addiction and Mental Health | 13 | 2012-09-01 | 2016-03-15 |
| Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes CVT-301, Placebo, Sinemet (carbidopa/levodopa) - Idiopathic Parkinson's Disease | Phase 2 | Completed | Acorda Therapeutics | 25 | 2012-05-01 | 2017-07-27 |
| Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease ABT-SLV187, Oral Levodopa/Carbidopa, Infusion Pump: CADD-Legacy® 1400 Pump - Advanced Parkinson's Disease | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 8 | 2011-10-01 | 2016-04-21 |
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 117 | 2011-05-01 | 2013-11-21 |
| Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens Carbidopa - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 27 | 2011-02-01 | 2011-09-12 |
| A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients Saline, Carbidopa - Parkinson's Disease | Phase 1 / Phase 2 | Completed | NeuroDerm Ltd. | 24 | 2011-01-01 | 2011-12-06 |
| A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa - Parkinson's Disease | Phase 2 | Completed | XenoPort, Inc. | 35 | 2010-07-01 | 2021-02-18 |
| An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill - Parkinson's Disease | Phase 1 / Phase 2 | Completed | XenoPort, Inc. | 14 | 2009-05-01 | 2021-05-05 |
Showing 20 of 26. Sign in to see all of them.
Parkinson Disease (12) · Pain (2) · Spinal Cord Injuries (2) · Autonomic Nervous System Diseases (1) · Cocaine-Related Disorders (1) · Cognitive Dysfunction (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Dysautonomia, Familial (1) · Dyskinesias (1) · Fatigue (1) · Fibromyalgia (1) · Hypertension (1) · Multiple Sclerosis (1) · Multiple System Atrophy (1)
Orion Corporation, Orion Pharma (3) · University of Michigan (3) · XenoPort, Inc. (2) · AbbVie (prior sponsor, Abbott) (1) · Acorda Therapeutics (1) · Centre for Addiction and Mental Health (1) · Chelsea Therapeutics (1) · Impel Pharmaceuticals (1) · Intec Pharma Ltd. (1) · Jessica M D'Amico (1) · NYU Langone Health (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · NeuroDerm Ltd. (1) · Oregon Health and Science University (1) · Second Affiliated Hospital of Wenzhou Medical University (1)
United States (14) · Canada (2) · Finland (2) · Israel (2) · United Kingdom (2) · Australia (1) · China (1) · Italy (1) · Luxembourg (1) · Serbia (1) · Spain (1) · Sweden (1)
Chatkaew Pongmala, PhD (2) · Jessica D'Amico, PhD (2) · Alfredo J Gamboa, MD (1) · BinBin Wu, doctor (1) · Claudia Trenkwalder, MD (1) · Dan Chen, M.D. (1) · David S Goldstein, M.D. (1) · Ephraim Heller, MBA (1) · Ernest Choy, M.D. (1) · Gary Remington, MD PhD FRCPC (1) · Horacio C Kaufmann, MD (1) · John G Nutt, MD (1) · John Grabowski, PhD (1) · Juha Rinne, Dr (1) · Kottil Rammohan, MD (1)
U01AG061393 (3), 2018 (1), P50DA009262 (1)